$CNSP News
Last published 2mo ago
- 2mo agoCNSPCNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of GrowthACCESS NewswireChief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc.
- 2mo agoCNSPCNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand ConferenceACCESS NewswireVideo webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. , a biotechnology company focused on building a pipeline
- 2mo agoAIMAKTXCNSPDARE+5JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsACCESS NewswireNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming
- 3mo agoCNSPCNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic TransformationACCESS NewswireCompany reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX /
- 5mo agoCNSPCNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" SegmentACCESS NewswireAccess the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. , a biotechnology company focused on building a pipeline of innovative therapies
- 5mo agoCNSPCNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation ProgressACCESS NewswireAccess the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. , a biotechnology company focused on building a pipeline of innovative
- 6mo agoCNSPCNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation ProgressACCESS NewswireOversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently
- 6mo agoCNSPCNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement FinancingACCESS NewswireThe private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare PartnersProceeds expected to enable CNS
- 8mo agoCNSPCNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology PipelineACCESS NewswireNewly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation driven by a
- 8mo agoCNSPCNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership TeamACCESS NewswireDr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company evolution
- 8mo agoCNSPCNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic TransformationACCESS NewswireNew Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value CreationHOUSTON, TX / ACCESS Newswire / February
- 9mo agoCNSPCNS Pharmaceuticals Issues Letter to ShareholdersACCESS NewswireNewly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term Value
- 10mo agoCNSPCNS Pharmaceuticals Announces CEO TransitionACCESS NewswireIndustry veteran Rami Levin, MBA appointed as President & Chief Executive OfficerHOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical
- 11mo agoCNSPCNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateACCESS NewswireCash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the blood-brain barrier,
- 1y agoCNSPCNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual MeetingACCESS NewswireHOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments
- 1y agoCNSPCNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceACCESS NewswireHOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments
- 1y agoCNSPIBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.GlobeNewswireAUSTIN, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of
- 1y agoAIMAKTXAMIXCNSP+5JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025ACCESS NewswireRegister for the three-day event here FRENCHTOWN, NJ / ACCESS Newswire / August 15, 2025 / JTC Team , a fully integrated corporate communications and investor relations firm, today announced its
- 1y agoCNSPCNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateACCESS NewswireStrong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme HOUSTON, TX / ACCESS
- 1y agoCNSPCNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechACCESS Newswire- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical
- 1y agoCNSPCNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand ConferenceACCESS Newswire– Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company
- 1y agoAIMAKTXAMIXCNSP+7JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand ConferenceACCESS Newswire- Video webcasts to be available on-demand Tuesday, July 22nd FRENCHTOWN, NJ / ACCESS Newswire / July 18, 2025 / JTC Team , a fully integrated corporate communications and investor relations firm, today
- 1y agoCNSPCNS Pharmaceuticals Announces Reverse Stock SplitACCESS NewswireHOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for
- 1y agoCNSPCNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287ACCESS NewswireModerated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS Pharmaceuticals,
- 1y agoCNSPCNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech SummitACCESS NewswireIn person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS
- 1y agoCNSPCNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdateACCESS NewswireCash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme HOUSTON,
- 1y agoCNSPCNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesACCESS NewswireHOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for
- 1y agoCNSPCNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287ACCESS NewswireCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme Management releases
- 1y agoCNSPCNS Pharmaceuticals Reports Full Year 2024 Financial ResultsACCESS NewswireCompany has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in
- 1y agoCNSPCNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma MultiformeACCESS NewswireBerubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety profile continues to be
- 1y agoCNSPCNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ ListingACCESS NewswireCash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. , a
- 1y agoCNSPCNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO ForumACCESS NewswireWebcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical
- 1y agoCNSPCNS Pharmaceuticals, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand ConferenceACCESS NewswireOn-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company
- 1y agoAKTXAMIXARECCNSP+5Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-DemandACCESS Newswire- Access video webcasts from the first wave of participating companies hereFRENCHTOWN, NJ / ACCESS Newswire / February 19, 2025 / JTC Team , a fully integrated corporate communications and investor
- 1y agoCNSPCNS Pharmaceuticals Announces Reverse Stock SplitACCESS NewswireHOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments
- 1y agoCNSPCNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development SummitACCESS NewswireHOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments
- 1y agoCNSPCNS Pharmaceuticals to Present at the BIO CEO & Investor ConferenceACCESS NewswireIn-person presentation today, February 10th at 1:15 PM ET HOUSTON, TX / ACCESS Newswire / February 10, 2025 / CNS Pharmaceuticals, Inc. , a biopharmaceutical
- 1y agoCNSPCNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024ACCESS NewswireLive webcast discussion featuring internationally renowned Glioblastoma Multiforme Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to
- 1y agoCNSPCNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line TherapyACCESS NewswirePoster presented at the 29th Annual Meeting of the Society for Neuro-Oncology Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX
- 1y agoCNSPCNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)ACCESS NewswireHOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for
- 1y agoCNSPCNS Pharmaceuticals Reports Third Quarter 2024 Financial ResultsACCESS NewswirePrimary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company strengthens cash position to extend runway to fund operations beyond data readout of
- 2y agoCNSPCNS Pharmaceuticals Announces Virtual Investor KOL Connect SegmentACCESS NewswireSegment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael WellerAccess the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc.
- 2y agoCNSPCNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price RequirementACCESS NewswireHOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for
- 2y agoCNSPCNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesACCESS NewswireHOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for
- 2y agoCNSPCNS Pharmaceuticals Participates in Virtual Investor KOL Connect SegmentACCESS NewswireSegment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel GoldlustAccess the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc.
- 2y agoCNSPCNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLCACCESS NewswireLive webcast fireside chat on Wednesday, October 16th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. , a biopharmaceutical
- 2y agoCNSPCNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe ForumACCESS NewswireWebcast presentation on Wednesday, September 25th at 1:55 PM CEST HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. , a biopharmaceutical
- 2y agoCNSPCNS Pharmaceuticals Regains Compliance with Nasdaq Equity RequirementACCESS NewswireHOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for
- 2y agoCNSPCNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceACCESS NewswireHOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for
- 2y agoCNSPIBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.GlobeNewswireLOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the